Oncology
Latest news
915 articles · 20 / page
Long-Term Nirogacestat for Progressive Desmoid Tumors: Durable Responses, Continued Tumor Shrinkage, and a Manageable Safety Profile
Extended follow-up from the phase III DeFi trial shows that continuous nirogacestat yields further tumor shrinkage, durable objective responses (ORR 45.7% at up to 4 years), sustained patient-reported benefits, and a consistent, manageable
NCI Working Group on Biochemically Recurrent Prostate Cancer: Trial Design Guidance for a PSMA Era
The NCI convened experts to provide clinical-trial design recommendations for biochemically recurrent prostate cancer in the era of PSMA PET, defining PSMA+BCR, high-risk criteria, imaging and data standards, endpoint suggestions, and a pus
PASS-01: Gemcitabine/Nab‑Paclitaxel Shows an Overall Survival Edge Over Modified FOLFIRINOX in First‑Line Metastatic PDAC — Biomarker Correlatives Underscore Need to Move Precision Upstream
In the randomized phase II PASS‑01 trial of first‑line metastatic pancreatic ductal adenocarcinoma (PDAC), progression‑free survival was similar between modified FOLFIRINOX and gemcitabine/nab‑paclitaxel, but overall survival and safety tre
Eryaspase Fails to Improve Survival in Second‑Line Advanced Pancreatic Cancer: Results from the Phase III TRYBECA‑1 Trial
In TRYBECA‑1, adding erythrocyte‑encapsulated L‑asparaginase (eryaspase) to second‑line chemotherapy did not improve overall survival, progression‑free survival, or response rates in advanced pancreatic ductal adenocarcinoma; adverse events
Glecirasib, Alone and with Cetuximab, Shows Activity in KRASG12C-Mutant Colorectal Cancer — Combination Nearly Doubles Response Rate
Phase 1/2 data show oral glecirasib has single-agent activity (ORR 23%) in KRASG12C colorectal cancer; adding cetuximab raises ORR to 50% with manageable toxicity, supporting further randomized testing and earlier-line combination strategie
Zelenectide Pevedotin Shows Early Activity in Advanced Nectin‑4–Expressing Tumors, With Promising Responses in Urothelial Carcinoma
First-in-human dose-escalation data for zelenectide pevedotin (BT8009), a Nectin‑4–targeted Bicycle Drug Conjugate, demonstrate tolerability and preliminary efficacy (ORR 24% overall; 38% in urothelial carcinoma) supporting further evaluati
Chromosome 1q Gain, Not Lung Nodule Burden, Best Predicts Outcomes in Stage IV Favorable‑Histology Wilms Tumor
In AREN0533, number and size of pulmonary metastases had limited prognostic value after standardized therapy; gain of chromosome 1q emerged as a stronger, independent predictor of event‑free and overall survival in children with favorable‑h
Neoadjuvant 177Lu-PSMA Before SBRT Doubles Progression-Free Survival in Oligorecurrent Hormone-Sensitive Prostate Cancer — Results from the LUNAR Phase II Trial
In the randomized phase II LUNAR trial, adding two cycles of neoadjuvant 177Lu-PNT2002 to stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer significantly prolonged progression-free survival (17.6 vs
Consensus Molecular Subtype 4 (CMS4) Identifies RAS Wild-Type mCRC Patients Who May Benefit Preferentially from Anti‑EGFR Therapy
An individual patient data meta-analysis of 790 RAS wild-type metastatic colorectal cancer patients suggests CMS4 tumors derive meaningful progression-free and overall survival benefit from anti‑EGFR versus anti‑VEGF antibodies, warranting
Neoadjuvant TQB2102 (Bispecific HER2-Directed ADC) Produces High Pathologic Complete Response Rates in Early and Locally Advanced HER2-Positive Breast Cancer
A randomized phase II trial of the bispecific HER2-directed ADC TQB2102 (n=104) showed robust total pathologic complete response rates (tpCR 57.7–76.9% across cohorts) with manageable grade ≥3 toxicity and no treatment‑related deaths, suppo
Eflornithine Plus Lomustine Extends Progression-Free and Overall Survival in Recurrent IDH‑Mutant Grade 3 Astrocytoma — Results from STELLAR Phase III
The STELLAR phase III trial found that eflornithine added to lomustine doubled PFS and significantly improved OS in patients with recurrent IDH‑mutant grade 3 astrocytoma after radiotherapy and temozolomide, with increased but manageable my
Amivantamab Plus Lazertinib Shows Promising Activity in Atypical EGFR-Mutant Advanced NSCLC: CHRYSALIS‑2 Cohort C Results
In CHRYSALIS‑2 Cohort C, the amivantamab plus lazertinib combination produced a 52% ORR and durable responses (mDoR 14.1 months) in advanced NSCLC with atypical EGFR mutations, with higher activity in treatment‑naïve patients and an expecte
Neoadjuvant TAR-200 (intravesical gemcitabine) plus cetrelimab shows improved pathologic responses and MRD signal utility in cisplatin-ineligible MIBC: Primary SunRISe-4 analysis
SunRISe-4 reports higher pCR, pOR, and 1‑year RFS for neoadjuvant TAR‑200 plus cetrelimab versus cetrelimab alone in cisplatin‑ineligible/refusing MIBC, with urinary and circulating tumor DNA MRD correlating with outcomes.
Atezolizumab Plus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer: Two Phase III Trials Fall Short of Practice‑Changing Benefit
Two randomized phase III trials tested adding atezolizumab to bevacizumab plus chemotherapy in recurrent ovarian cancer. Neither AGO‑OVAR 2.29/ENGOT‑ov34 (non‑platinum, platinum‑resistant) nor ATALANTE/ENGOT‑ov29 (platinum‑sensitive) met th
Pirtobrutinib Matches and May Surpass Ibrutinib in BTKi‑Naïve CLL/SLL: First Randomized Head‑to‑Head Results with Improved Cardiac Safety
In the first randomized comparison of pirtobrutinib versus ibrutinib in BTKi‑naïve CLL/SLL (N=662), pirtobrutinib met noninferiority for overall response and showed favorable early PFS trends and lower rates of atrial fibrillation and hyper
Postoperative ctDNA Identifies Stage III Colon Cancer Patients Who May Benefit from Adjuvant Celecoxib
A post hoc analysis of CALGB (Alliance)/SWOG 80702 shows postoperative ctDNA positivity strongly predicts recurrence and suggests adjuvant celecoxib improves DFS and OS in ctDNA-positive stage III colon cancer.
Minimally Invasive Pancreatoduodenectomy Is Noninferior to Open Surgery for 90‑Day Complications but Raises Important Safety and Generalizability Questions
An international randomized trial found minimally invasive pancreatoduodenectomy (mostly robotic) noninferior to open surgery for 90‑day overall complications and modestly faster functional recovery, with lower fistula and wound‑infection r
Low‑Dose IL‑2 after Lymphodepletion and TIL Infusion Offers Comparable Immune and Clinical Outcomes to High‑Dose IL‑2 in Metastatic Melanoma
A phase II study in metastatic melanoma found no major differences in response, circulating T‑cell phenotypes, or proliferative signals between high‑dose and low‑dose IL‑2 after lymphodepletion and tumor‑infiltrating lymphocyte (TIL) infusi
A 30-Day Mortality Risk Score After Proctectomy for Rectal Cancer: What the NCDB Tells Us and How to Use It
A validated NCDB-derived risk score using age, sex, race, comorbidity, stage, neoadjuvant therapy, length of stay and conversion identifies patients at markedly different 30-day mortality risk after proctectomy (0.8%–4.5%).
Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights
PALACE‑2 reports that preoperative pembrolizumab combined with chemoradiotherapy produced a 43.2% pathologic complete response in resectable, locally advanced esophageal squamous cell carcinoma, with acceptable short‑term survival and a hig
Browse by specialty
Open language-specific specialty feeds and department pages.